Antag Therapeutics ApS: Financial statements 2021
CVR: 38402056
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Antag Therapeutics ApS (CVR 38402056) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -13,085,955 and a net result of DKK -14,863,343 compared with DKK -12,353,317 the year before. Equity in the 2021 report amounted to DKK 10,857,598. The solvency ratio was 52.5%. The company had 6 employees in the financial year.
- Gross Profit
- DKK -13,085,955
- Profit/Loss
- DKK -14,863,343
- Equity
- DKK 10,857,598
- Total Assets
- DKK 20,671,087
- Employees
- 6
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -13.1M | -14.9M | 10.9M | 6 |
| 2020 | - | -10.9M | -12.4M | -9.8M | 7 |
| 2019 | - | -7.9M | -9.2M | 2.6M | 4 |
| 2018 | - | -3.1M | -4.4M | 11.8M | 4 |
| 2017 | - | -3.7M | -3.9M | 8.7M | 2 |
Official annual report
Find more companies like Antag Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
Antag Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK -10,925,243, and the net result was DKK -12,353,317.
As of June 28, 2021, Christine Theresa Fischette has joined the board of directors of Antag Therapeutics ApS.
About Antag Therapeutics ApS
Antag Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Antag Therapeutics IVS. The management consists of Philip Just Larsen. The board consists of Keith Richard Leonard Jr (chair), Alexander Volker Wilhelm Mayweg, Amit Kantilal Shah and Jørgen Søberg Petersen. The company's owners include Novo Holdings A/S, Dawn Holdco SCSp and Versant Venture Capital VII, L.P.. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -191,588,449 and a net result of DKK -200,999,582 compared with DKK -32,265,249 the year before. Equity in the 2025 report amounted to DKK 235,310.